Hudan Liu PhD

  Professor, Medical Research Institute, Wuhan University

  Tel: 86-27-68750308

  Email: hudanliu@whu.edu.cn

Education

2000-2005 PhD in Cell and Development Biology

Rutgers, the State University of New Jersey, USA

1997-2000 MS in Molecular Biology

Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences

1993-1997 BS in Biochemistry

Wuhan University

Professional Experience

2016-  Professor, Medical Research Institute, Zhongnan Hospital, Wuhan University

2011-2015 Professor, School of Pharmacy, Huazhong University of Science and Technology

2007-2011 Postdoctoral Fellow, Abramson Family Cancer Research Institute, University of Pennsylvania, Perelman School of Medicine, USA

2005-2007 Postdoctoral Researcher, Department of Cell Biology and Neurosciences, Rutgers University, USA

Honors

2020 National Distinguished Young Scholar

2018 Provincial Chutian Young Scholar

2017 Provincial Distinguished Young Scholar

Professional Affiliations

Chinese Association of Pathophysiology (Experimental Hematology) Broad member

Chinese Association for Physiological Sciences (Blood Physiology) Broad member

American Association for Cancer Research Member

International Society of Experimental Hematology Member

Chinese Society for Cell Biology Member

Chinese Pharmacological Society Member

Research Interest:

1. We focus on understanding molecular pathology of tumorigenesis using multiple in vitro and in vivo approaches with particular attentions on major oncogenes including MYC.

2. We attempt to develop novel, mechanism-based targeted or combination therapy in cancer treatment, and evaluate the efficacy and safety in pre-clinical models.

Selected Publications: (* corresponding author)

1. Hu J, Wang T, Xu J, Wu S, Wang L, Su H, Jiang J, Yue M, Wang J, Wang D, Li P, Zhou F, Liu Y, Qing G, Liu H*. WEE1 inhibition induces glutamine addiction in T-cell acute lymphoblastic leukemia. Haematologica. 2021, 106(7):1816-1827.

2. Jiang J, Wang J, Yue M, Cai X, Wang T, Wu C, Su H, Wang Y, Han M, Zhang Y, Zhu X, Jiang P, Li P, Sun Y, Xiao W, Feng H, Qing G, Liu H*. Direct Phosphorylation and Stabilization of MYC by Aurora B Kinase Promote T Cell Leukemogenesis. Cancer Cell. 2020, 37(2):200-215.

3. Wang J, Jiang J, Chen H, Wang L, Guo H, Yang L, Xiao D, Qing G*, Liu H*. FDA-approved drug screen identifies proteasome as a synthetic lethal target in MYC-driven neuroblastoma. Oncogene. 2019, 38(41):6737-6751.

4. Su H, Hu J, Huang L, Yang Y, Thenoz M, Kuchmiy A, Hu Y, Li P, Feng H, Zhou Y, Taghon T, Van Vlierberghe P, Qing G, Chen Z*, Liu H*. SHQ1 regulation of pre-RNA splicing is required for T-lymphoblastic leukemia cell survival. Nature Communications. 2018, 9(1):4281.

5. Yue M, Jiang J, Gao P, Liu H*, Qing G*. Oncogenic MYC activates a feedforward regulatory loop promoting essential amino acid metabolism and tumorigenesis. Cell Reports. 2017, 21(13): 3819-3832.

6. Wang Z, Hu Y, Xiao D, Wang J, Liu C, Xu Y, Shi X, Jiang P, Huang L, Li P, Liu H*, Qing G*. Stabilization of Notch1 by the Hsp90 Chaperon is Crucial for T Cell Leukemogenesis. Clinical Cancer Research. 2017, 23(14):3834-3846.

7. Hu Y, Su H, Ye Q, Wang Z, Huang L, Wang Q, Liu S, Chen S, Zhou J, Li P, Liu H*, Qing G*. DEPTOR is a direct NOTCH1 target that promotes proliferation and survival in T-cell leukemia. Oncogene. 2017, 36(8):1038-1047.

8. Hu Y, Su H, Li X, Guo G, Qin R, Qing G, Liu H*. Jagged2 promotes pancreatic cancer metastasis independent of Notch signaling activation. Molecular Cancer Therapeutics. 2015, 14(1): 289-297.